JP6896651B2 - 結晶性化合物 - Google Patents

結晶性化合物 Download PDF

Info

Publication number
JP6896651B2
JP6896651B2 JP2017565236A JP2017565236A JP6896651B2 JP 6896651 B2 JP6896651 B2 JP 6896651B2 JP 2017565236 A JP2017565236 A JP 2017565236A JP 2017565236 A JP2017565236 A JP 2017565236A JP 6896651 B2 JP6896651 B2 JP 6896651B2
Authority
JP
Japan
Prior art keywords
xrpd
crystal form
rays
measured
items
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017565236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517742A (ja
JP2018517742A5 (enExample
Inventor
アンソニー・アレクサンダー・マッキニー
フランクリン・バイマスター
ウォルター・ピスコースキー
フレッド・ジェイ・フライツ
ヨンライ・ヤン
デイビッド・エイ・エンガース
バレリヤ・スモレンスカヤ
ベンカト・クスクントラ
Original Assignee
オオツカアメリカファーマシューティカル、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オオツカアメリカファーマシューティカル、インコーポレイテッド filed Critical オオツカアメリカファーマシューティカル、インコーポレイテッド
Publication of JP2018517742A publication Critical patent/JP2018517742A/ja
Publication of JP2018517742A5 publication Critical patent/JP2018517742A5/ja
Priority to JP2021096354A priority Critical patent/JP7244575B2/ja
Application granted granted Critical
Publication of JP6896651B2 publication Critical patent/JP6896651B2/ja
Priority to JP2023036730A priority patent/JP7583851B2/ja
Priority to JP2024192608A priority patent/JP2025022896A/ja
Priority to JP2026027045A priority patent/JP2026083082A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
JP2017565236A 2015-06-17 2016-06-17 結晶性化合物 Active JP6896651B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021096354A JP7244575B2 (ja) 2015-06-17 2021-06-09 結晶性化合物
JP2023036730A JP7583851B2 (ja) 2015-06-17 2023-03-09 結晶性化合物
JP2024192608A JP2025022896A (ja) 2015-06-17 2024-11-01 結晶性化合物
JP2026027045A JP2026083082A (ja) 2015-06-17 2026-02-24 結晶性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181174P 2015-06-17 2015-06-17
US62/181,174 2015-06-17
PCT/US2016/038256 WO2016205762A1 (en) 2015-06-17 2016-06-17 Crystalline compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021096354A Division JP7244575B2 (ja) 2015-06-17 2021-06-09 結晶性化合物

Publications (3)

Publication Number Publication Date
JP2018517742A JP2018517742A (ja) 2018-07-05
JP2018517742A5 JP2018517742A5 (enExample) 2019-07-18
JP6896651B2 true JP6896651B2 (ja) 2021-06-30

Family

ID=57546597

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017565236A Active JP6896651B2 (ja) 2015-06-17 2016-06-17 結晶性化合物
JP2021096354A Active JP7244575B2 (ja) 2015-06-17 2021-06-09 結晶性化合物
JP2023036730A Active JP7583851B2 (ja) 2015-06-17 2023-03-09 結晶性化合物
JP2024192608A Pending JP2025022896A (ja) 2015-06-17 2024-11-01 結晶性化合物
JP2026027045A Pending JP2026083082A (ja) 2015-06-17 2026-02-24 結晶性化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021096354A Active JP7244575B2 (ja) 2015-06-17 2021-06-09 結晶性化合物
JP2023036730A Active JP7583851B2 (ja) 2015-06-17 2023-03-09 結晶性化合物
JP2024192608A Pending JP2025022896A (ja) 2015-06-17 2024-11-01 結晶性化合物
JP2026027045A Pending JP2026083082A (ja) 2015-06-17 2026-02-24 結晶性化合物

Country Status (25)

Country Link
US (6) US9708261B2 (enExample)
EP (3) EP4049997A1 (enExample)
JP (5) JP6896651B2 (enExample)
KR (1) KR102593783B1 (enExample)
CN (3) CN117466800A (enExample)
AU (2) AU2016279075C1 (enExample)
CA (2) CA3200692A1 (enExample)
CY (1) CY1125352T1 (enExample)
DK (1) DK3597189T3 (enExample)
ES (1) ES2922158T3 (enExample)
HK (1) HK1247125A1 (enExample)
HR (1) HRP20220829T1 (enExample)
HU (1) HUE059348T2 (enExample)
LT (1) LT3597189T (enExample)
MX (2) MX387591B (enExample)
MY (1) MY194868A (enExample)
NZ (2) NZ739044A (enExample)
PH (1) PH12017502324A1 (enExample)
PL (1) PL3597189T3 (enExample)
PT (1) PT3597189T (enExample)
SA (1) SA517390552B1 (enExample)
SG (1) SG10201911417PA (enExample)
SI (1) SI3597189T1 (enExample)
TW (1) TWI751998B (enExample)
WO (1) WO2016205762A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3080080A4 (en) * 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
ES2922158T3 (es) 2015-06-17 2022-09-09 Otsuka America Pharmaceutical Inc Compuestos cristalinos
US11149004B2 (en) 2017-12-11 2021-10-19 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of EB-1020, processes for preparation and use thereof
CN114555557A (zh) * 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法
US12698260B2 (en) * 2021-05-31 2026-08-04 Assia Chemical Industries Ltd. Solid state form of centanafadine HCL and process for preparation thereof
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005117630A (ru) 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CA2619817A1 (en) 2004-08-18 2006-03-02 Dov Pharmaceutical, Inc. Thermodynamically stable polymorph of an azabicyclohexane
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080058535A1 (en) * 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
EP2819516B1 (en) * 2011-07-30 2019-12-25 Otsuka America Pharmaceutical, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
EP3080080A4 (en) 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
ES2922158T3 (es) 2015-06-17 2022-09-09 Otsuka America Pharmaceutical Inc Compuestos cristalinos

Also Published As

Publication number Publication date
WO2016205762A1 (en) 2016-12-22
JP2026083082A (ja) 2026-05-19
TW201800392A (zh) 2018-01-01
EP3597189B1 (en) 2022-06-01
AU2021200314B2 (en) 2022-08-04
HUE059348T2 (hu) 2022-11-28
EP3310352A4 (en) 2019-03-13
JP2018517742A (ja) 2018-07-05
JP2021138747A (ja) 2021-09-16
US11299458B2 (en) 2022-04-12
PL3597189T3 (pl) 2022-07-25
EP3310352A1 (en) 2018-04-25
LT3597189T (lt) 2022-07-11
KR20180014830A (ko) 2018-02-09
US9708261B2 (en) 2017-07-18
CN117088802A (zh) 2023-11-21
SG10201911417PA (en) 2020-01-30
US9856217B2 (en) 2018-01-02
AU2016279075B2 (en) 2020-10-22
CN117466800A (zh) 2024-01-30
SI3597189T1 (sl) 2022-08-31
DK3597189T3 (da) 2022-06-27
ES2922158T3 (es) 2022-09-09
CA3200692A1 (en) 2016-12-22
TWI751998B (zh) 2022-01-11
JP7583851B2 (ja) 2024-11-14
NZ739044A (en) 2022-08-26
US20210198198A1 (en) 2021-07-01
US20170334850A1 (en) 2017-11-23
AU2021200314A1 (en) 2021-03-18
HRP20220829T1 (hr) 2022-12-23
HK1247125A1 (zh) 2018-09-21
RU2018101244A (ru) 2019-07-22
US20260138950A1 (en) 2026-05-21
US20180194726A1 (en) 2018-07-12
CA2989431A1 (en) 2016-12-22
CN107921021A (zh) 2018-04-17
MY194868A (en) 2022-12-21
EP4049997A1 (en) 2022-08-31
US10280141B2 (en) 2019-05-07
MX2017016430A (es) 2018-11-09
MX387591B (es) 2025-03-18
US20160368871A1 (en) 2016-12-22
CA2989431C (en) 2023-08-29
JP2023071978A (ja) 2023-05-23
EP3597189A1 (en) 2020-01-22
US20200039934A1 (en) 2020-02-06
KR102593783B1 (ko) 2023-10-25
MX2020009949A (es) 2020-10-16
PT3597189T (pt) 2022-07-05
AU2016279075C1 (en) 2021-04-01
JP2025022896A (ja) 2025-02-14
CY1125352T1 (el) 2025-05-09
NZ776973A (en) 2022-11-25
PH12017502324A1 (en) 2018-06-25
SA517390552B1 (ar) 2022-04-13
JP7244575B2 (ja) 2023-03-22
RU2018101244A3 (enExample) 2019-12-23
AU2016279075A1 (en) 2018-02-01
US10800740B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
JP7583851B2 (ja) 結晶性化合物
JP2018517742A5 (enExample)
KR20140075703A (ko) 프리도피딘 하이드로클로라이드의 다형 형태
Singh et al. A new polymorph of ciprofloxacin saccharinate: Structural characterization and pharmaceutical profile
RU2789672C2 (ru) Кристаллические соединения
US6825193B2 (en) Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
HK40077679A (en) Crystalline compounds
HK40020220B (en) Crystalline compounds
HK40020220A (en) Crystalline compounds
HK40102359A (en) Crystalline compounds
HK40099983A (en) Crystalline compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210609

R150 Certificate of patent or registration of utility model

Ref document number: 6896651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250